{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T15:56:05Z","timestamp":1792684565299,"version":"4.5.0"},"reference-count":23,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,7,3]],"date-time":"2025-07-03T00:00:00Z","timestamp":1751500800000},"content-version":"vor","delay-in-days":367,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100018043","name":"Kitzman Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100018043","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007197","name":"U.S. Public Health Service","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007197","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100018268","name":"Children's Miracle Network Hospitals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100018268","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Therapy"],"published-print":{"date-parts":[[2024,7]]},"DOI":"10.1016\/j.ymthe.2024.06.009","type":"journal-article","created":{"date-parts":[[2024,6,21]],"date-time":"2024-06-21T01:10:21Z","timestamp":1718932221000},"page":"2042-2044","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["AAV vectors for long-term gene therapy of hemophilia B: Are we there yet?"],"prefix":"10.1016","volume":"32","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1168-8034","authenticated-orcid":false,"given":"Arun","family":"Srivastava","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ymthe.2024.06.009_bib1","unstructured":"2022. https:\/\/www.fda.gov\/vaccines-blood-biologics\/vaccines\/hemgenix."},{"key":"10.1016\/j.ymthe.2024.06.009_bib2","unstructured":"2024. https:\/\/www.fda.gov\/vaccines-blood-biologics\/cellular-gene-therapy-products\/beqvez"},{"key":"10.1016\/j.ymthe.2024.06.009_bib3","doi-asserted-by":"crossref","first-page":"2064","DOI":"10.1016\/j.ymthe.2024.05.005","volume":"32","author":"Pekrun","year":"2024","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2024.06.009_bib4","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1038\/nm1358","article-title":"Successful transduction of liver in hemophilia by AAV-factor IX and limitations imposed by the host immune response","volume":"12","author":"Manno","year":"2006","journal-title":"Nat. Med."},{"key":"10.1016\/j.ymthe.2024.06.009_bib5","doi-asserted-by":"crossref","first-page":"1994","DOI":"10.1056\/NEJMoa1407309","article-title":"Long-term safety and efficacy of factor IX gene therapy in hemophilia B","volume":"371","author":"Nathwani","year":"2014","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.ymthe.2024.06.009_bib6","doi-asserted-by":"crossref","first-page":"2357","DOI":"10.1056\/NEJMoa1108046","article-title":"Adenovirus-associated virus vector-mediated gene transfer in hemophilia B","volume":"365","author":"Nathwani","year":"2011","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.ymthe.2024.06.009_bib7","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1182\/blood.2019004625","article-title":"BAX 335 hemophilia B gene therapy clinical trial results: potential impact of CpG sequences on gene expression","volume":"137","author":"Konkle","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.ymthe.2024.06.009_bib8","doi-asserted-by":"crossref","first-page":"2215","DOI":"10.1056\/NEJMoa1708538","article-title":"Hemophilia B gene therapy with a high-specific-activity factor IX variant","volume":"377","author":"George","year":"2017","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.ymthe.2024.06.009_bib9","author":"Semedo"},{"key":"10.1016\/j.ymthe.2024.06.009_bib10","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1182\/blood-2017-09-804419","article-title":"Gene therapy with adeno-associated virus vector 5-human factor IX in adults with hemophilia B","volume":"131","author":"Miesbach","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.ymthe.2024.06.009_bib11","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1056\/NEJMoa2119913","article-title":"Phase 1-2 Trial of AAVS3 Gene Therapy in Patients with Hemophilia B","volume":"387","author":"Chowdary","year":"2022","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.ymthe.2024.06.009_bib12","doi-asserted-by":"crossref","first-page":"e504","DOI":"10.1016\/S2352-3026(22)00113-2","article-title":"Safety and activity of an engineered, liver-tropic adeno-associated virus vector expressing a hyperactive Padua factor IX administered with prophylactic glucocorticoids in patients with haemophilia B: a single-centre, single-arm, phase 1, pilot trial","volume":"9","author":"Xue","year":"2022","journal-title":"Lancet Haematol."},{"key":"10.1016\/j.ymthe.2024.06.009_bib13","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1007\/s40265-024-02017-4","article-title":"Fidanacogene elaparvovec: first approval","volume":"84","author":"Dhillon","year":"2024","journal-title":"Drugs"},{"key":"10.1016\/j.ymthe.2024.06.009_bib14","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1038\/nm1549","article-title":"CD8+ T-cell responses to adeno-associated virus capsid in humans","volume":"13","author":"Mingozzi","year":"2007","journal-title":"Nat. Med."},{"key":"10.1016\/j.ymthe.2024.06.009_bib15","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/j.ymgme.2009.05.010","article-title":"AAV3-mediated transfer and expression of the pyruvate dehydrogenase E1 alpha subunit gene causes metabolic remodeling and apoptosis of human liver cancer cells","volume":"98","author":"Glushakova","year":"2009","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymthe.2024.06.009_bib16","doi-asserted-by":"crossref","first-page":"1741","DOI":"10.1089\/hum.2010.075","article-title":"Human hepatocyte growth factor receptor is a cellular coreceptor for adeno-associated virus serotype 3","volume":"21","author":"Ling","year":"2010","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.ymthe.2024.06.009_bib17","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1038\/nature12875","article-title":"Selection and evaluation of clinically relevant AAV variants in a xenograft liver model","volume":"506","author":"Lisowski","year":"2014","journal-title":"Nature"},{"key":"10.1016\/j.ymthe.2024.06.009_bib18","doi-asserted-by":"crossref","first-page":"1867","DOI":"10.1038\/mt.2015.174","article-title":"Efficient and targeted transduction of nonhuman primate liver with systemically delivered optimized AAV3B vectors","volume":"23","author":"Li","year":"2015","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2024.06.009_bib19","doi-asserted-by":"crossref","first-page":"1877","DOI":"10.1038\/mt.2015.179","article-title":"Comparative study of liver gene transfer with AAV vectors based on natural and engineered AAV capsids","volume":"23","author":"Wang","year":"2015","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2024.06.009_bib20","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1038\/mt.2016.61","article-title":"Superior in\u00a0vivo transduction of human hepatocytes using engineered AAV3 capsid","volume":"24","author":"Vercauteren","year":"2016","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2024.06.009_bib21","doi-asserted-by":"crossref","first-page":"e131610","DOI":"10.1172\/jci.insight.131610","article-title":"Using a barcoded AAV capsid library to select for clinically relevant gene therapy vectors","volume":"4","author":"Pekrun","year":"2019","journal-title":"JCI Insight"},{"key":"10.1016\/j.ymthe.2024.06.009_bib22","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1089\/hum.2020.099","article-title":"Development of a clinical candidate AAV3 vector for gene therapy of hemophilia B","volume":"31","author":"Brown","year":"2020","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.ymthe.2024.06.009_bib23","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.omtm.2021.08.001","article-title":"Coagulation factor IX gene transfer to non-human primates using engineered AAV3 capsid and hepatic optimized expression cassette","volume":"23","author":"Kumar","year":"2021","journal-title":"Mol. Ther. Meth. Cin. Dev."}],"container-title":["Molecular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525001624003915?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525001624003915?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,7,3]],"date-time":"2025-07-03T12:48:47Z","timestamp":1751546927000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1525001624003915"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7]]},"references-count":23,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2024,7]]}},"alternative-id":["S1525001624003915"],"URL":"https:\/\/doi.org\/10.1016\/j.ymthe.2024.06.009","relation":{},"ISSN":["1525-0016"],"issn-type":[{"value":"1525-0016","type":"print"}],"subject":[],"published":{"date-parts":[[2024,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"AAV vectors for long-term gene therapy of hemophilia B: Are we there yet?","name":"articletitle","label":"Article Title"},{"value":"Molecular Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ymthe.2024.06.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The American Society of Gene and Cell Therapy. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}